132014-73-4

Upstream product

• 132991-79-8 4-methylbenzenesulfonic acid [5-oxo-1-(phenylmethyl)-(2S)-pyrrolidinyl]methyl ester 
• 77539-18-5 (S)-(+)-2-benzylamino glutaric acid 
• 38854-94-3 N-benzyl-L-pyroglutamic acid 
• 103301-78-6 methyl (2S)-1-benzyl-5-pyrrolidone-2-carboxylate 
• 100-52-7 benzaldehyde 
• 56-86-0 L-glutamic acid 
• 125629-91-6 (S)-5-(hydroxymethyl)-1-(phenylmethyl)-2-pyrrolidinone 

Downstream Products

• 131879-92-0 (5S,1'S)-5-<(3'-ethoxy-5'-oxocyclohex-3'-en-1'-yl)methyl>-1-(phenylmethyl)pyrrolidin-2-one 
• 131879-89-5 (S)-5-oxo-1-(phenylmethyl)-2-pyrrolidineacetaldehyde 
• 131879-90-8 (E)-4-<2(R)-5-oxo-1-(phenylmethyl)-2-pyrrolidinyl>-2-butenoic acid ethyl ester 
• 131879-94-2 (5S,1R)-5-<(3-methyl-5-oxo-3-cyclohexen-1-yl)methyl>-1-(phenylmethyl)-2-pyrrolidinone 
• 131879-91-9 (S)-5-<<5-oxo-1-(phenylmethyl)-2-pyrrolidinyl>methyl>-1,3-cyclohexanedione 
• 131879-98-6 (1R,3R,5S,5(2S))-3-methyl-5-<<5-oxo-1-(phenylmethyl)-2-pyrrolidinyl>methyl>cyclohexaneacetic acid 
• 131880-14-3 (1R,3R,5S,5(2S))-3-methyl-5-<<5-oxo-1-(phenylmethyl)-2-pyrrolidinyl>methyl>cyclohexaneacetamide 
• 131879-97-5 (1R,3R,5S,5(2S))-3-methyl-5-<<5-oxo-1-(phenylmethyl)-2-pyrrolidinyl>methyl>cyclohexaneacetic acid ethyl ester 
• 131879-93-1 (5S,1S)-5-<(3-ethoxy-5-oxo-3-cyclohexen-1-yl)methyl>-1-(phenylmethyl)-2-pyrrolidinone 
• 132014-74-5 (S)-1-(phenylmethyl)-5-(2-propenyl)-2-pyrrolidinone 

Relevant academic research and scientific papers

Peptide Mimetics of Thyrotropin-Releasing Hormone Based on a Cyclohexane Framework: Design, Synthesis, and Cognition-Enhancing Properties

The design and synthesis of peptide mimetics of thyrotropin-releasing hormone (TRH) in which the peptide backbone is entirely replaced by a cyclohexane framework are described.The cis-1,3,5-trisubstituted ring was expected to permit key pharmacophoric gro

[(5-oxo)-2-pyrrolidinyl)methyl]cyclohexaneacetamides, compositions and use

[(5-oxo-2-pyrrolidinyl)methyl]cyclohexaneacetamides of the formula STR1 wherein R1 is hydrogen, lower alkyl or aryl-lower alkyl; R2 is hydrogen, lower alkyl, aryl, aryl-lower alkyl, STR2 wherein R5 and R6 are hydrogen, lower alkyl or aryl-lower alkyl; R3 and R4, independently, are hydrogen, lower alkyl, or aryl-lower alkyl; and enantiomers, diastereomers, and racemates thereof, and, when R2 is STR3 pharmaceutically acceptable acid addition salts thereof, are described. The compounds of formula I exhibit cognitive enhancement and antiamnestic activity and are therefore useful, for example, in treating memory deficits associated with Alzheimer's disease or age-associated memory impairment.